Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor Cells

This publication has 51 references indexed in Scilit:

• The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels
  Oncogene, 2001
• p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements
  Oncogene, 2001
• p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells
  Cell Death & Differentiation, 1999
• Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress
  Oncogene, 1999
• Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionSelfcloseTable
  Oncogene, 1997
• TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains
  Genes, Chromosomes and Cancer, 1995
• Apoptotic cell death induced by a mouse‐human anti‐APO‐1 chimeric antibody leads to tumor regression
  International Journal of Cancer, 1994
• Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family
  Cell, 1993
• The p53 tumour suppressor gene
  Nature, 1991
• Mutations in the p53 gene occur in diverse human tumour types
  Nature, 1989